Business Wire10h
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...
Cure Today6h
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
The American Journal of Managed Care14h
The Impact of ADT for Prostate Cancer on Survival and Patient Well-Being
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
Most pancreatic cancer isn’t caught until it’s late stage — a new blood test could change that
The American Cancer Society estimates that 67,400 Americans will be diagnosed with pancreatic cancer this year and nearly ...
Hosted on MSN9h
Blood Test for Early Pancreatic Cancer Shows Promise
He noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...
UroToday13h
ASCO GU 2025: Early Detection of Recurrent Prostate Cancer Using 18F-DCFPyL PET/CT in Patients with Minimal PSA Levels
Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a prostate cancer poster session. Dr. Ida Sonni presented a study evaluating the diagnostic performance of 18 ...